default author photo

Glenn Hamonic

University of Saskatchewan - Vaccine and Infectious Disease Organization

Saskatoon

Canada

  • University of Saskatchewan - Vaccine and Infectious Disease Organization

SCHOLARLY PAPERS

3

DOWNLOADS

263

TOTAL CITATIONS

0

Scholarly Papers (3)

Actions:
Email selected abstracts
1.

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Downloads 170 (442,467)

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Number of pages: 28 Posted: 21 Aug 2024
Trina Racine, Glenn Hamonic, Elodie Pastural, Supriya Arora, Jocelyne Lew, Yun Cai, Erin Scruten, Rachelle Buchannan, May ElSherif, Lingyun Ye, Thomas Courant, Roland A. Ventura, Nicolas Collin, Matthieu Daugan, Luc Gagnon, Paul Hodgson, Sylvia van Drunen Little van den Hurk, Darryl Falzarano, Steve Sanche, Scott A. Halperin, Joanne Marie Langley and Volker Gerdts
University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Canadian Center for Vaccinology, Dalhousie University, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Vaccine Formulation Institute (VFI), Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan, Dalhousie University, Dalhousie University and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 119 (602,987)

Abstract:

Loading...

COVID-19 vaccine, protein subunit, Sepivac SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Number of pages: 33 Posted: 08 Aug 2025
Glenn Hamonic, Elodie Pastural, Supriya Arora, Jocelyne Lew, Yun Cai, Erin Scruten, Rachelle Buchannan, May ElSherif, Lingyun Ye, Thomas Courant, Roland A. Ventura, Nicolas Collin, Matthieu Daugan, Luc Gagnon, Paul Hodgson, Sylvia van Drunen Little van den Hurk, Darryl Falzarano, Steve Sanche, Scott A. Halperin, Joanne Marie Langley, Volker Gerdts and Trina Racine
University of Saskatchewan - Vaccine and Infectious Disease Organization, affiliation not provided to SSRN, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Canadian Center for Vaccinology, Dalhousie University, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Nexelis/Q2 Solutions, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan, Dalhousie University, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 51 (1,072,374)

Abstract:

Loading...

COVID-19 vaccine, protein subunit, SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1

2.

Efficacy of a Stable Broadly Protective Subunit Vaccine Platform Against Sars-Cov-2 Variants of Concern

Number of pages: 43 Posted: 18 Apr 2024
Ravendra Garg, Qiang Liu, Jill Van Kessel, Akarin Asavajaru, Eva-Maria Uhlemann, Morgane Joessel, Glenn Hamonic, Zahed Khatooni, Andrea Kroeker, Jocelyne Lew, Erin Scruten, Paul Pennington, William Deck, Tracy Prysliak, Michaela Nickol, Falko Apel, Thomas Courant, Alyson Kelvin, Andrew G. van Kessel, Nicolas Collin, Volker Gerdts, Wolfgang Köster, Darryl Falzarano, Trina Racine and Arinjay Banerjee
University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 55 (1,010,164)

Abstract:

Loading...

SARS-CoV-2, subunit vaccine, broad protection, vaccine platform, emerging coronaviruses, Syrian hamsters

3.

A Spike-Accum® Bioconjugate Protein Vaccine Confers Potent SARS-COV-2-Specific Immunity

Number of pages: 62 Posted: 02 Dec 2024
Jean Pierre Bikorimana, Nathanael A. Caveney, Nehme El-Hachem, Gabrielle Arona Mandl, John A. Capobianco, Daniela Stanga, Jamilah Abusarah, Mark Hancock, Roudy Farah, Marina Gonçalves, Darryl Falzarano, Mingmin Liao, Glenn Hamonic, Qiang Liu, Simon Beaudoin, Sebastien Talbot, Moutih Rafei and Sneak Peek Administrator
University of Montreal - Department of Microbiology, Infectious Diseases and Immunology, University of Toronto, University of Montreal - CHU Sainte-Justine Research Center, University of Montreal - Department of Microbiology, Infectious Diseases and Immunology, Concordia University, Defence Therapeutics Inc, University of Montreal - Department of Pharmacology and Physiology, McGill University, University of Montreal - Department of Microbiology, Infectious Diseases and Immunology, Defence Therapeutics Inc, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Defence Therapeutics Inc, Queen’s University, University of Montreal - Department of Pharmacology and Physiology and Independent
Downloads 38 (1,209,354)

Abstract:

Loading...